Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 2/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.47 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.47 |
| ▸ | ATR | Q13535 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31298011 | 0.92 | L3MBTL3 (0.52) | KDM1AMAOAMAOBMCHR1L3MBTL3 | |
| SCHEMBL31298102 | 0.91 | GAA (0.44) | KDM1AMAOAMAOBMCHR1L3MBTL3 | |
| SCHEMBL6403300 | 0.81 | GAA (0.47) | GAA | |
| SCHEMBL10293555 | 0.79 | L3MBTL3 (0.69) | KDM1AMAOAMAOBL3MBTL3ATR | |
| SCHEMBL10293598 | 0.79 | L3MBTL3 (0.69) | KDM1AMAOAMAOBL3MBTL3ATR | |
| SCHEMBL31298071 | 0.76 | GAA (0.43) | GAA | |
| SCHEMBL31297972 | 0.75 | HRH4 (0.45) | GAAHDAC1 | |
| SCHEMBL31298051 | 0.74 | KMT2A (0.62) | NPSR1GAA | |
| SCHEMBL8917126 | 0.73 | L3MBTL3 (0.84) | L3MBTL3 | |
| SCHEMBL2889406 | 0.72 | MCHR1 (0.73) | MCHR1L3MBTL3ATRHRH3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | MILLENNIUM PHARM INC (US) | 2025-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250043353-A1 | BIOMARKERS OF RESPONSE TO SELECTIVE INHIBITORS OF AURORA A KINASE | WNT1, XPOT, CTNNBL1 | KDM1A 2299/4885MAOA 3660/4885MAOB 3792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.